All In MedTech

FDA Clearance Tracker · P040050-S013

Macroplastique Implants

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 9, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 9, 2023

Approved

Time to decision

361 days

Received May 13, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P040050-S013
Device name
Macroplastique Implants
Applicant location
Minnetonka, MN
Received
May 13, 2022
Decided
May 9, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P040050

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

Approval for modifying the labeling to reflect the findings of the Macroplastique Real-Time Observation of Safety and Effectiveness (ROSE) Registry.

Source documents

Other decisions for Uroplasty, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.